loading...| Preferred Name |
Hydromorphone Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt form of hydromorphone, the hydrogenated ketone of morphine, a semi-synthetic opioid with analgesic effects. Hydromorphone selectively binds the mu-opioid receptor which is linked through G-proteins. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex and interacts with and inhibits adenylate cyclase located at the inner surface of the plasma membrane. This leads to a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP). Further, voltage-gated potassium channels are activated, thereby causing hyperpolarization and reducing neuronal excitability. In addition, the opening of voltage-gated calcium channels is inhibited, thereby leading to an inhibition of calcium entry and a reduction in the release of various neurotransmitters, including GABA, vasopressin, somatostatin, insulin and glucagons. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C436 |
|
| Accepted_Therapeutic_Use_For |
pain in opioid-tolerant patients. |
|
| CAS_Registry |
71-68-1 |
|
| CHEBI_ID |
CHEBI:5791 |
|
| Chemical_Formula |
C17H19NO3.HCl |
|
| code |
C436 |
|
| Contributing_Source |
CPTAC FDA |
|
| definition |
The hydrochloride salt form of hydromorphone, the hydrogenated ketone of morphine, a semi-synthetic opioid with analgesic effects. Hydromorphone selectively binds the mu-opioid receptor which is linked through G-proteins. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex and interacts with and inhibits adenylate cyclase located at the inner surface of the plasma membrane. This leads to a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP). Further, voltage-gated potassium channels are activated, thereby causing hyperpolarization and reducing neuronal excitability. In addition, the opening of voltage-gated calcium channels is inhibited, thereby leading to an inhibition of calcium entry and a reduction in the release of various neurotransmitters, including GABA, vasopressin, somatostatin, insulin and glucagons. |
|
| FDA_UNII_Code |
L960UP2KRW |
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C156952 |
|
| label |
Hydromorphone Hydrochloride |
|
| Legacy Concept Name |
Hydromorphone |
|
| NCI_Drug_Dictionary_ID |
574280 |
|
| NSC Number |
19046 |
|
| PDQ_Closed_Trial_Search_ID |
574280 |
|
| PDQ_Open_Trial_Search_ID |
574280 |
|
| Preferred_Name |
Hydromorphone Hydrochloride |
|
| prefixIRI |
NCIT:C436 |
|
| prefLabel |
Hydromorphone Hydrochloride |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0700533 |
|
| subClassOf |